Fair Value Calculator Fair Value Calculator
EN DE

HEALTHYLIFE (HEALTHYLIFE) Fair Value & Analysis

IN · Market cap ₹331M

H HEALTHYLIFE HEALTHYLIFE · BSE
Price₹6.67
Fair Value₹14.50
Upside+117.4%
Quality28/100
Watch HEALTHYLIFE for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹10.28 – ₹18.72

Fair value as of: Jul 5, 2026

From 15 valuation models · updated today

Share price +10.4% over the past month.

Price vs Fair Value (12 months)

₹72.78 ₹5.65 Fair Value ₹14.50 Jul 2025 Jul 2026

12‑month range ₹5.65 – ₹72.78 · fair‑value band ₹10.28 – ₹18.72 · the ₹6.67 price screens below the ₹14.50 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

HEALTHYLIFE (HEALTHYLIFE) currently trades at ₹6.67, while our model-based Fair Value estimate is ₹14.50 — implying the stock looks roughly 117.4% undervalued today. We read business quality at 28/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, HEALTHYLIFE generated revenue of ₹2.3B at a net margin of 1.8%. Revenue grew 95.6% year over year. It earns a return on equity of 8.2%. Net debt stands at ₹118M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹10.28 (bear case) to ₹18.72 (bull case); at ₹6.67, the current price sits below that range.

Key figures & financial health

Revenue (TTM) ₹2.3B
Revenue growth (YoY) +95.6%
Net margin 1.8%
Return on equity 8.2%
Free cash flow −₹285M FY2026
P/E ratio 8.2
More key figures
Operating margin 2.2%
EPS (TTM) ₹0.8100
EPS growth (YoY) -36.4%
Net debt ₹118M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

HEALTHYLIFE reported revenue of ₹2.3B in FY2026 versus ₹340M in FY2022, a compound +61.0%/yr. Reported net income was ₹40.0M in FY2026, compounding +48.8%/yr from FY2022.

Revenue +61.0%/yr
FY22 ₹340M
FY23 ₹1.1B
FY24 ₹1.3B
FY25 ₹1.7B
FY26 ₹2.3B
Net income +48.8%/yr
FY22 ₹8.1M
FY23 ₹15.1M
FY24 ₹25.1M
FY25 ₹32.6M
FY26 ₹40.0M

Is HEALTHYLIFE fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "HEALTHYLIFE Fair Value". https://www.fairvalue-calculator.com/stock/HEALTHYLIFE

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is HEALTHYLIFE (HEALTHYLIFE) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹14.50 versus a price of ₹6.67 — about +117% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HEALTHYLIFE?
Our model-based fair value for HEALTHYLIFE is ₹14.50 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹6.67.
What is the quality score of HEALTHYLIFE?
HEALTHYLIFE has a Quality Score of 28/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of HEALTHYLIFE (HEALTHYLIFE)?
HEALTHYLIFE reported trailing-twelve-month revenue of about ₹2.3B (latest available figure, as of Jul 5, 2026).
What is the net profit margin of HEALTHYLIFE?
The net profit margin of HEALTHYLIFE is about 1.8%, meaning it keeps roughly 1.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.